Markets:

Overview

News

Currencies

International

Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

129.41 +2.13 (+1.67%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Essex Investment Buys $7.1 Million Globalstar Stake as Revenue Hits Record High ↗

November 09, 2025

Essex Investment Buys $7.1 Million Globalstar Stake as Revenue Hits Record High

Via The Motley Fool

Topics Regulatory Compliance

Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today ↗

October 31, 2025

Via Benzinga

Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗

October 30, 2025

Via Benzinga

Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗

October 30, 2025

Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.

Via Investor's Business Daily

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

A Preview Of Insmed's Earnings ↗

October 29, 2025

Via Benzinga

Analyst Expectations For Insmed's Future ↗

October 02, 2025

Via Benzinga

Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗

October 30, 2025

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome...

Via Benzinga

Topics Economy

Here's How Much $1000 Invested In Insmed 5 Years Ago Would Be Worth Today ↗

October 23, 2025

Via Benzinga

This Is What Whales Are Betting On Insmed ↗

October 15, 2025

Via Benzinga

Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today ↗

October 07, 2025

Via Benzinga

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗

September 30, 2025

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

Via Benzinga

Spotlight on Insmed: Analyzing the Surge in Options Activity ↗

September 25, 2025

Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed (NASDAQ: INSM) revealed 29 unusual trades.

Via Benzinga

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today ↗

September 22, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 09, 2025

Via Benzinga

Deep Dive Into Insmed Stock: Analyst Perspectives (26 Ratings) ↗

September 03, 2025

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It ↗

September 02, 2025

The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition.

Via Investor's Business Daily

Israel Englander's Millennium Goes All-In On Crypto And Healthcare While Rebalancing Big Tech Bets: Bitcoin ETF And Palantir Stakes Soar In Q2 ↗

August 27, 2025

Millennium Management's Q2 2025 13F reveals big bets on crypto (IBIT, PLTR) & healthcare (EW, INSM), with tech rebalancing. Read key changes!

Via Benzinga

Topics ETFs

Why Electromed Stock Jumped 12% After-Hours: A Rival’s Weakness And A New Drug Tailwind ↗

August 26, 2025

The after-hours surge came as management pointed to hospital market share gains from a distracted competitor and rising bronchiectasis awareness following Insmed’s FDA-approved drug launch.

Via Stocktwits

Topics Earnings

$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today ↗

August 21, 2025

Via Benzinga

Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 21, 2025

Via Benzinga

Lung Disease-Focused Insmed 'Must-Own' Name For Investors ↗

August 20, 2025

Insmed gains FDA approval for Brinsupri in bronchiectasis, while analysts see multi-billion sales potential from its expanding pipeline through 2035

Via Benzinga

Intel, UnitedHealth, And Reddit Are Among Top Large Cap Gainers Last Week (August 11-August 15): Are The Others In Your Portfolio? ↗

August 17, 2025

These 10 large-cap stocks gained this week, some due to positive news such as media rights deals or FDA approvals.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

August 14, 2025

Via Benzinga

Assessing Insmed: Insights From 20 Financial Analysts ↗

August 13, 2025

Via Benzinga

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week ↗

August 13, 2025

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.

Via Stocktwits

Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

August 13, 2025

Via Benzinga

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic ↗

August 13, 2025

Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.

Via Stocktwits

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease ↗

August 12, 2025

The FDA approves Insmed's Brinsupri for NCFB, cutting exacerbations and slowing the decline of lung function in Phase 3 trial patients.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.